💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control &

#astro25 @NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT. Negative trial -OS no difference -PCSM no difference -DM no difference -BCR was not SS different with only 4% difference at 10 years. -toxicity increased 3 cooperative group trials now negative:

✨Our '' rising '' star, @ConstanceHuck discussing TMT in the context of CIS, with @UroDocAsh. 👂Listen this excellent discussion here @urotoday following the paper published in @EUplatinum https://t.co/loh4kbsQU1

📫 Interim results of #Sunrise4 are released @TheLancetOncol Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC ✅ TAR200+CET: pCR 42%, Major path Response 60% ✅ in cT2 pts baseline: pCR 48% ✅ TAR200 exposure-response association: pCR 50% if TAR200x4

✍️🇫🇷 SFRO: FRENCH GUIDELINES FOR THE ROLE OF RADIOTHERAPY IN THE MANAGEMENT OF BLADDER CANCER @SFjROfr https://t.co/SKvHnAHM13

🚨 MUST READ 🚨 🔥 Bladder preservation with CIS? Time to rethink the rules. 👉 New in EUO: https://t.co/Daj2uxZ0WB 🙏 Grateful to the amazing team! #BladderCancer #Urology #RadiationTherapy #BladderPreservation #CIS

How to manage gynecomastia with ARPIs monotherapy? A review by @nassimVibert 🙏 https://t.co/K9X0rDjJ6C #ProstateCancer #Prostate #life

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb! ➡️link https://t.co/VYvAn6kli1

EAU Guidelines Update: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines by Antoine G. van der Heijden et al Read the full update here: https://t.co/F1YBkwzR2N #UroSoMe #MedTwitter #EurUrol

New insights on SBRT in recurrent ovarian cancer – now in CTRO: “SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review” 👉 https://t.co/AbnJgiAnoH 🎯 Local control ⏳ Delayed systemic therapy ⚖️ Personalized strategy @EORTC

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

@shilpaonc @AndreaNecchi @drjefstathiou @DrChoueiri @DrRanaMcKay @montypal @DrRosenbergMSK @IBCG_BladderCA We have performed a review dedicated to this topic... Just submitted. 🙏 With @ConstanceHuck @Achard_Verane @evanguelosx @MRoupret @BertrandTOMBAL @drjefstathiou @vandammeju @achoud72 ✨Trial to come... 🤞 @Achard_Verane

🌞Une superbe édition des RR 2024 avec un groupe dynamique d'oncologues, urologues et radiothérapeutes. 🌞Tout sur le cancer de la prostate dans un programme interactif🤝 👉On se retrouve pour la 3e en 2025 ! @PignotG @AlbertoBossial @stephaneculine @jacquesirani @RenardPennaR

✨Our systematic review focusing on TMT and concomitant Chemo regimen for patients with MIBC 👉 Heterogeneity ++ 👉Overall, similar OS and safety outcomes 👉Highest LOE=5FU-Mitomycin C 👉Data regarding elderly patients and QOL insufficiently reported https://t.co/1SywQMbfje

Addition of RT to the primary in mHSPC #PEACE1 For the low volume population: 🔴No OS benefit 🟢rPFS benefit for patients treated with abiraterone In the overall population: 🟢Reduction of the occurence of serious GU events https://t.co/xZkLWqIUAq

✨More than happy to have the Australian Goat @_ShankarSiva in #Bordeaux to talk about the last innovations in the management of GU tumors 💪 @BERGONIE33 @CHUBordeaux

DEBATE : 🇫🇷🇮🇳🇨🇦TMT is A standard of Care ⚡Inform patients, they need to see a radonc and a urologist and a medical oncologist 👉Work to do: How to define complete response after TMT? MRI for better local staging? 🌍No need to have underwears to come in @FocusMeeting 🙏Thanks

Prostate #SBRT after prior TURP? Useful points in this latest review led by @ConstanceHuck and @ZilliThomas in @ctRO_journal @ESTRO_RT https://t.co/pmQDLr4lBA

Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity ⁦@Achard_Verane⁩ ⁦@VedangMurthy⁩ ⁦@docpriyamvada⁩

Prostate SBRT after TURP: feasible, but careful patient selection after multiple TURP and adenomectomy. Impact of post-surgical cavity resection volume? ⁦@Achard_Verane⁩ ⁦@VedangMurthy⁩